Bioxcel therapeutics announces last patient last visit in serenity at-home pivotal phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia

Vast majority of patients dosed completed the full 12-week study data from more than 2,200 agitation episodes collected topline data readout anticipated this month new haven, conn., aug. 01, 2025 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced completion of the last patient last visit (lplv) in the pivotal phase 3 serenity at-home clinical trial.
BTAI Ratings Summary
BTAI Quant Ranking